Effect of a Probiotic on the Female Genital Tract Microbiota of Participants With Fertility Disorders.

NCT ID: NCT06122207

Last Updated: 2025-06-03

Basic Information

• Recruitment Status: RECRUITING
• Clinical Phase: NA
• Total Enrollment: 120 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2024-02-14
• Study Completion Date: 2025-10-31

Brief Summary

In the last decades, numerous publications have broken the old paradigm that considered the urogenital tracts as sterile, demonstrating that microorganisms present in the urogenital tract represent the 9% of the whole human microbiome. Healthy urogenital microbiome improves implantation rate and pregnancy outcomes, whereas 40% of dysbiosis prevalence is observed in women under assisted reproductive treatment (ART).

Infertility causes are associated with male, female, or combined failure. It has been shown that oral probiotic treatment, mainly with Lactobacillus, recovers a healthy vaginal microbiota without safety concerns.

An interventional, randomized, double-blind, placebo-controlled study will be conducted to confirm the positive effect of the commercial probiotic product Fertibiome® on the vaginal dysbiosis of couples or women with fertility disorders.

The duration of the study will be of 6 months approximately, including 6 months of product intake. In case of pregnancy during intervention, women will continue their participation until week 12 of gestation.

Participants will be randomly assigned to one of the two study groups: control group with placebo administration or probiotic administration group. Women will take 1 capsule every 12 hours and men 1 per day. In case of women participating alone they will take 1 capsule every 12 hours. In case of pregnancy, only women will continue taking 1 capsule per day for the first 12 weeks.

Conditions

Fertility Disorders

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: TRIPLE

Study Groups

Probiotic

Women will take two daily doses containing approximately 2*10E9 Colony Forming Unit (CFU) of Ligilactobacillus salivarius PS11610 (Fertibiome®). Men will take one daily dose containing approximately 1*10E9 CFU of Ligilactobacillus salivarius PS11610 (Fertibiome®).

In case of pregnancy during intervention, only women will continue taking 1 daily dose for the first 12 weeks of gestation.

Group Type: ACTIVE_COMPARATOR

Probiotic

Intervention Type: DIETARY_SUPPLEMENT

• Women: 1 capsule of probiotic (Ligilactobacillus salivarius PS11610) every 12 hours for 6-months. In case of pregnancy:

• Women: 1 capsule of probiotic per day for 12 weeks.
• Men: 1 capsule of probiotic (Ligilactobacillus salivarius PS11610) per day for 6-months.

Placebo

Women will take two daily doses of Placebo supplement. Men will take one daily dose of Placebo supplement.

In case of pregnancy during intervention, only women will continue taking 1 daily dose for the first 12 weeks of gestation.

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: DIETARY_SUPPLEMENT

• Women: 1 capsule of placebo every 12 hours for 6-months. In case of pregnancy:

• Women:1 capsule of placebo per day for 12 weeks.
• Men: 1 capsule of placebo per day for 6-months.

Interventions

Probiotic

• Women: 1 capsule of probiotic (Ligilactobacillus salivarius PS11610) every 12 hours for 6-months. In case of pregnancy:

• Women: 1 capsule of probiotic per day for 12 weeks.
• Men: 1 capsule of probiotic (Ligilactobacillus salivarius PS11610) per day for 6-months.

Intervention Type: DIETARY_SUPPLEMENT

Placebo

• Women: 1 capsule of placebo every 12 hours for 6-months. In case of pregnancy:

• Women:1 capsule of placebo per day for 12 weeks.
• Men: 1 capsule of placebo per day for 6-months.

Intervention Type: DIETARY_SUPPLEMENT

Eligibility Criteria

Inclusion Criteria

• Couples or women with ages between 18 and 40 for woman and between 18 and 55 for man (in case of couple participation).
• Couples or women with fertility disorders.
• Couples or women undergoing IVF treatment or willing to start it.
• Signature of the Informed Consent.

Exclusion Criteria

• Women, not participating in the study with a couple, who have not undergone at least 4 cycles of artificial insemination with donor's sperm (AID) or 1 cycle of IVF without achieving evolutionary pregnancy.
• Women with Body Mass Index (BMI) ≥ 30.
• Couples where the woman has not infertility diagnosis while the man has any of the following characteristics:

• Azoospermia
• Sperm motility (A + B) < 25%.
• Sperm morphology ≤ 2%.
• Vas deferens obstruction.
• Couples or women with any of the following characteristics:

• Chronic diseases that cause intestinal malabsortion.
• Congenital or acquired immunodeficiency.
• Current history or diagnosis of alcohol, tobacco, or drug abuse.
• Uncertainty about the willingness or ability of participants to comply with the requirements of the protocol.
• Under treatment with probiotics during the last week.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 40 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

ProbiSearch SL

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

Dr. Miguel Raimundo (Portugal)

Lisbon, , Portugal

Site Status: RECRUITING

Hospital Universitario La Paz

Madrid, Madrid, Spain

Site Status: RECRUITING

Countries

Portugal; Spain

Central Contacts

Susana Manzano Jiménez, PhD

Role: CONTACT

susana.manzano@probisearch.com

918035179

Facility Contacts

Miguel Raimundo, MD

Role: primary

Silvia Iniesta Pérez, MD, PhD

Role: primary

Other Identifiers

FEC/23.03

Identifier Type: -

Identifier Source: org_study_id